Axa
FATE icon

Axa’s Fate Therapeutics FATE Stock Holding History

Axa’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,200
Closed -$1.2M – 1246
2020
Q4 		$1.2M Hold
13,200
– – ﹤0.01% 941
2020
Q3 		$528K Hold
13,200
– – ﹤0.01% 1031
2020
Q2 		$453K Sell
13,200
-12,700
-49% -$379K ﹤0.01% 1080
2020
Q1 		$575K Buy
+25,900
New +$655K ﹤0.01% 947

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Axa's FATE Position: Q1 2021 in Review

Axa sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 13,200 shares — an estimated $1.2M sold.

Axa first reported a position in FATE in Q1 2020 and held it in 4 quarters. The position peaked at $1.2M in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

  • Axa reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Axa sold 13,200 Fate Therapeutics shares in Q1 2021, an estimated $1.2M.
  • Axa first reported a position in Fate Therapeutics in Q1 2020 and held it in 4 quarters.
  • Axa's Fate Therapeutics position peaked at $1.2M in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.